Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 1 | 2025 | 36 | 0.890 |
Why?
|
| Boron Neutron Capture Therapy | 1 | 2023 | 1 | 0.820 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 186 | 0.810 |
Why?
|
| Radiosurgery | 2 | 2020 | 84 | 0.750 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 311 | 0.650 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2020 | 41 | 0.640 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2020 | 65 | 0.620 |
Why?
|
| Apoptosis | 5 | 2014 | 777 | 0.580 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 6 | 0.450 |
Why?
|
| Genomic Instability | 1 | 2014 | 34 | 0.440 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 86 | 0.440 |
Why?
|
| Neoplasms | 1 | 2023 | 857 | 0.420 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 121 | 0.400 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 300 | 0.360 |
Why?
|
| Gastrointestinal Stromal Tumors | 3 | 2014 | 12 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2014 | 12 | 0.220 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 2045 | 0.220 |
Why?
|
| Humans | 11 | 2025 | 28585 | 0.210 |
Why?
|
| Boron | 1 | 2023 | 1 | 0.200 |
Why?
|
| Boron Compounds | 1 | 2023 | 5 | 0.200 |
Why?
|
| Radiobiology | 1 | 2023 | 5 | 0.200 |
Why?
|
| Female | 5 | 2025 | 15472 | 0.180 |
Why?
|
| Mastectomy | 1 | 2021 | 22 | 0.170 |
Why?
|
| Nanotechnology | 1 | 2021 | 68 | 0.170 |
Why?
|
| Nanomedicine | 1 | 2021 | 62 | 0.170 |
Why?
|
| Glioblastoma | 1 | 2021 | 109 | 0.160 |
Why?
|
| Artifacts | 1 | 2020 | 50 | 0.160 |
Why?
|
| Aged | 3 | 2020 | 5525 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2019 | 265 | 0.140 |
Why?
|
| Middle Aged | 3 | 2020 | 7310 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2021 | 291 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 282 | 0.130 |
Why?
|
| Prognosis | 2 | 2019 | 807 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 681 | 0.120 |
Why?
|
| Animals | 4 | 2025 | 10583 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 472 | 0.120 |
Why?
|
| Autocrine Communication | 1 | 2014 | 7 | 0.110 |
Why?
|
| HT29 Cells | 1 | 2014 | 20 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2014 | 10 | 0.110 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 12 | 0.110 |
Why?
|
| HCT116 Cells | 1 | 2014 | 53 | 0.110 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2014 | 22 | 0.110 |
Why?
|
| Necrosis | 1 | 2014 | 85 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2014 | 58 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 194 | 0.110 |
Why?
|
| Male | 3 | 2020 | 13772 | 0.100 |
Why?
|
| Transfection | 1 | 2014 | 319 | 0.100 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2013 | 1 | 0.100 |
Why?
|
| Hepatocytes | 1 | 2014 | 80 | 0.100 |
Why?
|
| Benzamides | 1 | 2013 | 34 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 41 | 0.100 |
Why?
|
| Cell Survival | 1 | 2014 | 416 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 344 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 50 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2013 | 119 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2013 | 128 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 453 | 0.090 |
Why?
|
| Phenotype | 1 | 2014 | 682 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 465 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 671 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2014 | 817 | 0.090 |
Why?
|
| Adult | 2 | 2020 | 7922 | 0.090 |
Why?
|
| Time Factors | 1 | 2014 | 1600 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2014 | 1455 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2009 | 9 | 0.080 |
Why?
|
| Pyrazines | 1 | 2009 | 24 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2021 | 2612 | 0.050 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2021 | 32 | 0.040 |
Why?
|
| Florida | 1 | 2021 | 55 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 130 | 0.040 |
Why?
|
| Stem Cells | 1 | 2021 | 122 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2021 | 119 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 157 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 236 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2021 | 229 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 1341 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 504 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 1026 | 0.030 |
Why?
|
| Caspase Inhibitors | 1 | 2014 | 8 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2014 | 24 | 0.030 |
Why?
|
| Mice | 2 | 2014 | 4735 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2014 | 2 | 0.030 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2014 | 5 | 0.030 |
Why?
|
| Plicamycin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 103 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 284 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2014 | 97 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2013 | 15 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 314 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 354 | 0.020 |
Why?
|
| Cell Death | 1 | 2013 | 119 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 97 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2014 | 332 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 695 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 404 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1056 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 137 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 12 | 0.020 |
Why?
|
| Bortezomib | 1 | 2009 | 22 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 114 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 68 | 0.020 |
Why?
|
| Histones | 1 | 2009 | 95 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 328 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 291 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 417 | 0.020 |
Why?
|